Poor
Needs Revision
Patient Risk:
High
Summary
Several statements are inconsistent with the provided label excerpts or are unsupported. Mechanism is partially aligned, but multiple specific interaction claims (herbs/supplements) and broad adverse event/monitoring claims are not supported by the provided labeling. Indication/disease-risk statements are partially aligned but lack the label’s conditional language and scope.
Category Scores
Accurate Statements
Lipitor (atorvastatin) blocks the production of cholesterol in the liver.
Supported by mechanism of action excerpt: LIPITOR is an HMG-CoA reductase inhibitor (Section 12.1).
Grapefruit and grapefruit juice can increase the levels of Lipitor in the blood.
Supported by grapefruit juice interaction excerpt: can increase plasma concentrations of atorvastatin (Section 7.2).
St. John's Wort can decrease the levels of Lipitor in the blood.
Not supported by provided excerpts.
Unsupported Statements
By reducing the amount of cholesterol in the blood, Lipitor helps to lower the risk of heart disease, heart attacks, and strokes.
Label excerpt supports specific cardiovascular risk reductions (Section 1.1), but the provided label text uses specific indications/conditions and includes terms like myocardial infarction and stroke; the statement is too broad and does not reflect the label’s indication-specific population framing.
Grapefruit and grapefruit juice can increase the risk of side effects such as muscle pain, liver damage, and kidney problems when taken with Lipitor.
Provided label excerpt for grapefruit juice addresses increased atorvastatin plasma concentrations (Section 7.2) but does not state grapefruit increases risk of muscle pain/liver damage/kidney problems.
St. John's Wort can decrease the levels of Lipitor in the blood.
No St. John's Wort interaction is included in the provided labeling excerpts (Section 7).
St. John's Wort can make Lipitor less effective in lowering cholesterol levels.
No St. John's Wort interaction or efficacy statement is included in the provided labeling excerpts.
St. John's Wort can increase the risk of heart disease and other cardiovascular problems.
No St. John's Wort interaction or cardiovascular risk increase is included in the provided labeling excerpts.
Red yeast rice can interact with Lipitor.
No red yeast rice interaction is included in the provided labeling excerpts.
Red yeast rice can increase the risk of muscle damage and liver problems when taken with Lipitor.
No red yeast rice interaction or risk statement is included in the provided labeling excerpts.
Fenugreek can increase the levels of Lipitor in the blood.
No fenugreek interaction is included in the provided labeling excerpts.
Fenugreek can increase the risk of side effects such as muscle pain, liver damage, and kidney problems when taken with Lipitor.
No fenugreek interaction or risk statement is included in the provided labeling excerpts.
Ginkgo biloba can increase the risk of bleeding when taken with Lipitor.
No ginkgo biloba interaction is included in the provided labeling excerpts.
Omega-3 fatty acids can increase the risk of bleeding when taken with Lipitor.
No omega-3 fatty acids interaction is included in the provided labeling excerpts.
Vitamin E can increase the risk of bleeding when taken with Lipitor.
No vitamin E interaction is included in the provided labeling excerpts.
Coenzyme Q10 (CoQ10) can increase the risk of muscle damage when taken with Lipitor.
No CoQ10 interaction is included in the provided labeling excerpts.
Common side effects of Lipitor include muscle pain, liver damage, and kidney problems.
The provided adverse reactions excerpts list myalgia and liver enzyme increases, and rhabdomyolysis/renal failure is mentioned in the skeletal muscle warning context, but the statement incorrectly frames these as 'common side effects' and includes 'kidney problems' without label support for commonness.
Regular blood tests can be used to monitor cholesterol levels and liver function in people taking Lipitor.
Label excerpt supports lipid level analysis after initiation/titration (Section 2.1) and liver function tests prior to and at 12 weeks after initiation and with dose increases/elevations (Section 5.2), but it does not state 'regular' cholesterol monitoring in general or 'kidney function' testing.
Contradictions
Low
AI Statement
Lipitor (atorvastatin) blocks the production of cholesterol in the liver.
Label Reference
No direct contradiction in provided excerpts; mechanism is consistent (Section 12.1).
Important Omissions
No mention of contraindications from provided excerpts: active liver disease and pregnancy (women who are pregnant or may become pregnant), and nursing avoidance (women requiring LIPITOR treatment should not breastfeed).
Importance:
Moderate
No mention of label-supported grapefruit juice limitation guidance (>1.2 liters per day) and dose-related CYP3A4 inhibitor precautions (e.g., caution when LIPITOR dose exceeds 20 mg with certain inhibitors).
Importance:
Moderate
No mention of label-supported monitoring specifics for liver function tests (prior to initiation; at 12 weeks following initiation; and with dose increases or elevations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple supplement/herb interaction claims (St. John's Wort, red yeast rice, fenugreek, ginkgo, omega-3, vitamin E, CoQ10) are not supported by the provided label excerpts and could lead to unsafe or inaccurate medication/supplement assumptions. The 'common side effects' framing and 'kidney problems' inclusion are not clearly supported as 'common' in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Many interaction and safety assertions are unsupported by the provided FDA label excerpts (Sections 7, 6). Several statements are overly broad (indications/risk reduction framing) or inaccurately characterized (common side effects; grapefruit adverse effects).
Suggested Improvement
Restrict claims to what is supported in the provided excerpts: (1) use label’s specific cardiovascular risk-reduction indications and population conditions (Section 1.1), (2) keep grapefruit interaction to plasma concentration increase and dosing cautions described (Section 7.2), (3) remove herb/supplement interaction claims not present in provided Section 7, (4) use label-supported adverse reaction terms and monitoring recommendations (Sections 5.2, 2.1) rather than broad 'common side effects' lists.